FAM78A

Across TCGA pan-cancer cohorts, FAM78A Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FAM78A data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher FAM78A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM78A expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LUSC, THCA, and ESCA are the cancer types where FAM78A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.079	0.746	<.001	36	view →
THCA	DFS	Median	All	0.106	0.841	<.001	6	view →
ESCA	OS	Median	All	0.147	0.700	.002	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	All	0.361	0.786	.044	3	view →
BLCA	DFS	Median	IV	1.000	0.307	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FAM78A–LUSC (OS)

Open the LUSC breakdown →